Patients on Ozempic, Wegovy, and other GLP-1 receptor agonist medications are showing up in dermatologists' offices with something their prescribing physicians may not have anticipated: dramatically improved skin.
A Medscape report published July 9, 2026 synthesized emerging clinical observations and new genetic research suggesting that GLP-1 drugs may offer significant benefits for two of the most difficult-to-treat chronic inflammatory skin diseases — psoriasis and hidradenitis suppurativa (HS). One dermatologist profiled in the report described seeing patients with psoriasis experience nearly complete skin clearance on GLP-1 therapy alone.
Early research suggests GLP-1 medications can help reduce the inflammation involved in conditions like psoriasis and hidradenitis suppurativa, particularly in patients who also have obesity or diabetes. These medications are not FDA-approved for either skin condition, and dermatologists stress that more controlled clinical research is needed before any formal recommendations can be made. But the combination of clinical signals and new genetic evidence is attracting serious attention in dermatology.
Why This Matters
Psoriasis affects approximately 7.5 million Americans, according to the American Academy of Dermatology. It is a chronic immune-mediated disease characterized by thick, scaly plaques that can affect the scalp, elbows, knees, and other areas. Beyond the physical discomfort, psoriasis carries a significant psychological burden and is associated with a substantially elevated risk of psoriatic arthritis, cardiovascular disease, and metabolic syndrome.
Hidradenitis suppurativa is a chronic, often misunderstood skin condition that causes painful, boil-like lumps in areas where skin rubs together — the armpits, groin, and inner thighs. It is frequently misdiagnosed for years before a correct diagnosis is made. It is closely linked to obesity, metabolic dysfunction, and smoking. Both conditions share a common thread: systemic inflammation — the same biological pathway that GLP-1 drugs appear to modulate.
A question is arising more frequently in dermatology clinic settings: patients with psoriasis or HS who are starting GLP-1 medications for obesity or diabetes want to know whether those drugs might also help their skin. The short answer, based on emerging evidence, is: possibly — and new genetic research suggests the benefit may extend beyond what weight loss alone explains.
What We Know So Far
The most important piece of new evidence comes from a Mendelian randomization study published in the British Journal of Dermatology in April 2026. Mendelian randomization uses naturally occurring genetic variation to approximate the long-term effect of a biological factor, helping separate causal effects from confounding.
The study found that people genetically predisposed to have higher GLP-1 receptor expression had a significantly lower risk of developing psoriasis — with an odds ratio of 0.72 — and an even lower risk of developing psoriatic arthritis, with an odds ratio of 0.48. Those numbers translate to meaningful reductions in disease risk.
Critically, the associations remained consistent after multivariable adjustment for metabolic traits — meaning the protective effect was not fully explained by the metabolic benefits of GLP-1 receptor activity, such as lower BMI or improved blood sugar control. This suggests a direct immunological role for GLP-1 signaling in psoriatic disease that operates independent of weight loss.
Supporting this, GLP-1 receptor expression has been found to be upregulated in psoriatic lesional skin, and preclinical studies have shown that GLP-1 pathways may modulate IL-17 and TNF-alpha signaling — two of the key inflammatory drivers in psoriasis. A meta-analysis of four cohort studies and two randomized trials found a pooled reduction in Psoriasis Area and Severity Index scores of 5.8 points among patients on GLP-1 therapy, though the studies were small and methodologically limited.
A Tufts Medical Center retrospective chart review published in the Journal of Drugs in Dermatology in April 2026 examined 1,490 patients with psoriasis or HS. It confirmed that meaningful gaps exist in GLP-1 counseling for these patients — many of whom are metabolically eligible for GLP-1 therapy but are not being advised about it by either their dermatologists or primary care providers.
Where the Clinical Evidence Is Strongest
Psoriasis is currently the condition with the most supportive evidence base, and it is where GLP-1 research in dermatology is most advanced. Ravi Ramessur, co-lead author of the British Journal of Dermatology genetic study, told Medscape that psoriasis is the clear frontrunner for future clinical trials and that there are still unanswered questions about HS and whether there's benefit there — with clinical trials using GLP-1s specifically for skin disease in development.
For HS, the evidence base is less mature. The biological rationale is strong — HS is closely linked to obesity and metabolic dysfunction, and weight loss alone can produce meaningful clinical improvement in HS severity. But whether GLP-1s produce effects on HS that go beyond weight loss has not yet been established in clinical trials.
Psoriatic arthritis, the joint disease that develops in approximately 30 percent of people with psoriasis, showed the strongest risk reduction in the Mendelian randomization data — an odds ratio of 0.48 — suggesting that GLP-1 signaling may have particularly meaningful effects at the intersection of skin and joint inflammation.
What Doctors and Experts Say
A dermatologist profiled in the Medscape report described one of his own patients with psoriasis experiencing nearly complete skin clearance on GLP-1 therapy alone — a result that prompted him to dig into the research. He found himself looking back at a 2011 paper that first linked GLP-1 drugs to an anti-inflammatory response in T cells in the skin lesions of two patients with psoriasis and type 2 diabetes.
Gary Goldenberg, MD, assistant clinical professor of dermatology at the Icahn School of Medicine at Mount Sinai and dermatologist at Mount Sinai Hospital in New York City, told Yahoo Health that early research suggests GLP-1 medications can help reduce inflammation in psoriasis and HS, particularly in patients who also have obesity or diabetes. He emphasized that the drugs are not FDA-approved for either skin condition and that controlled, long-term dermatology-focused studies are still needed.
Writing in Practical Dermatology, dermatologists framed the clinical question as one that is increasingly arising in practice: for patients with psoriasis or HS who are metabolically eligible for GLP-1 therapy — meaning they have a BMI over 30, or a BMI over 27 with a metabolic comorbidity — the drugs represent a reasonable addition to the clinical discussion. For patients who are not metabolically eligible for GLP-1 therapy under current prescribing guidelines, the evidence does not yet support off-label use purely for a skin indication.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Genetic study type: Mendelian randomization using cis-expression quantitative trait loci (cis-eQTLs) as proxies for GLP-1 receptor expression
- Published in: British Journal of Dermatology, April 2026 (DOI: 10.1093/bjd/ljag163)
- Lead authors: Ravi Ramessur et al., including collaborators from King's College London, Norwegian University of Science and Technology, and University of Pennsylvania
- What the genetic study found: Higher GLP-1 receptor expression genetically associated with 28% lower psoriasis risk and 52% lower psoriatic arthritis risk; effects persisted after adjusting for metabolic traits
- Clinical meta-analysis finding: Mean PASI reduction of 5.8 points across six small studies
- What the evidence does not yet prove: Whether GLP-1 drugs, when prescribed specifically for psoriasis or HS, will produce clinically significant improvements in controlled trials; whether benefits extend to patients without metabolic comorbidities
- FDA approval status: GLP-1 drugs are not approved for psoriasis or hidradenitis suppurativa
- What readers should know: Patients with psoriasis or HS who are metabolically eligible for a GLP-1 medication should ask their clinician whether it may be appropriate for their situation. Do not seek these drugs off-label for skin conditions alone without clinical guidance.
Who Might Benefit Most?
Based on the available evidence, patients most likely to see skin benefit from GLP-1 therapy are those who:
- Have both psoriasis or HS and obesity (BMI over 30) or relevant metabolic comorbidities such as type 2 diabetes, obstructive sleep apnea, or cardiovascular disease
- Are already on GLP-1 medication for a metabolic indication and have wondered whether it is affecting their skin
- Have psoriasis that has not been adequately controlled with topical therapies alone
- Have HS with significant inflammatory burden and concurrent obesity
Patients with severe psoriasis already on biologic medications may experience additional benefit from GLP-1 therapy if they are metabolically eligible, though clinician-supervised assessment is essential given potential drug interactions and individual variability.
Symptoms and Warning Signs to Watch For
Patients who start a GLP-1 medication for weight management or diabetes and notice either:
- Improvement in skin plaque thickness, redness, or scaling (psoriasis), or
- Reduction in the frequency or severity of HS lesions
should document these changes and report them to their dermatologist at the next visit. Dermatologists are increasingly interested in tracking these outcomes, and formal documentation supports the development of the evidence base.
Conversely, some patients report skin changes on GLP-1 medications that are adverse — including injection-site reactions and, in some cases, hair thinning associated with rapid weight loss. Any unexpected skin change should be reported to a clinician.
What You Can Do Now
- If you have psoriasis or hidradenitis suppurativa and are being considered for a GLP-1 medication for obesity or diabetes, ask your prescribing physician and your dermatologist to discuss this research together.
- If you are already on a GLP-1 medication and have noticed changes in your skin condition, document those changes — noting when the change began relative to your medication start date — and share them with your dermatologist.
- Do not seek GLP-1 medications specifically as a treatment for psoriasis or HS outside of appropriate metabolic clinical guidelines. These drugs are not FDA-approved for skin indications, and off-label prescribing for skin alone is not supported by current evidence.
- Ask your dermatologist whether clinical trials evaluating GLP-1s for psoriasis or HS are enrolling near you. Trials are expected to launch as the evidence base strengthens.
- Track updates through the American Academy of Dermatology and National Psoriasis Foundation , both of which publish lay-language summaries of emerging clinical research.
Cost and Access: What Patients Should Know
GLP-1 medications — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are among the most expensive prescription drugs on the market, with monthly costs ranging from $900 to $1,400 before insurance. Coverage varies by plan and indication. Insurance plans that cover GLP-1 drugs for type 2 diabetes are generally more willing to cover them than plans covering the drugs for obesity alone.
Patients with psoriasis or HS who are also eligible for GLP-1 therapy based on metabolic criteria may find that coverage for the diabetes or obesity indication is available even if the skin benefit is not the formally listed reason. Patient assistance programs from Novo Nordisk (for Wegovy and Ozempic) and Eli Lilly (for Zepbound and Mounjaro) are available for patients who meet income eligibility criteria.
What Happens Next
Clinical trials specifically designed to test GLP-1 drugs as treatments for psoriasis are in development. Ravi Ramessur told Medscape that researchers are moving toward clinical trials using GLP-1s specifically to help answer whether the observed benefit in psoriasis reflects a direct immunological effect. Results from such trials would be the first robust evidence to support or refute the current observational and genetic findings. MedicalDaily will report when trial results are published.
The Bottom Line
GLP-1 drugs are showing up in dermatology clinics in a new way: not as cause for concern, but as unexpected therapeutic agents. The emerging evidence — from clinical observations, a genetic study in the British Journal of Dermatology, and a Tufts Medical Center retrospective study — suggests that GLP-1 receptor activity may reduce inflammation in psoriatic disease through mechanisms independent of weight loss. The evidence is not yet strong enough to recommend GLP-1 drugs specifically for skin conditions. But for the millions of Americans with psoriasis or HS who are also metabolically eligible for these medications, this research adds a meaningful dimension to the conversation with their doctors.
